# Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

> **NCT00251368** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 52 (estimated)

## Conditions studied

- Leukemia, Myelocytic, Acute
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** 9-Aminocamptothecin (9-AC)

## Key facts

- **NCT ID:** NCT00251368
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-01
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2011-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251368, "Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00251368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*